Derma Science to Start Phase 2 Studies of DSC127 for Wound Healing
Diabetic ulcers are extremely painful, take a very long time to heal, and in many cases, they do not heal and the person ends up having to have the foot, leg or other extremities that are affected by ulcers amputated.
DSC127 Phase 1 Clinical Studies
The drug that is being called DSC127 is entering phase 2 of the human clinical studies. The first phase was performed on 12 weeks with 75 participants. It was a double blind study (as phase 2 will also be) where half the participants where given the DSC127 and the other half where given a placebo. The results were positive and the final results will be made public by January 2011.
What Derma Science Has to Say About DSC127
“DSC127 up regulates a cassette of genes at the site of skin healing. These genes are involved in energy metabolism (glycolysis and electron transport), oxidative stress and production of cytoskeletal proteins, all of which could be involved in the growth of new skin during wound healing. This finding suggests that DSC127 produces different actions at the wound site during various stages of healing. DSC127 appears to stimulate production of dermal adult progenitor cells, including mesenchymal stem cells, following injury.”
Source: Derma Science, Inc.